Drug intelligence / Profile preview

PB2202

Development stage: Unknown
Lead developer: PB Immune Therapeutics

Overview

PB2202 is a human biologic therapeutic candidate developed by PB Immune Therapeutics for the treatment of Graft-versus-Host Disease (GvHD). The drug is part of a pipeline focused on precision immunology, utilizing the company's proprietary ImmuneDict platform, which integrates single-cell transcriptomics and proteomics to identify novel therapeutic targets. PB2202 is designed to address the immune dysregulation characteristic of GvHD, a serious complication of hematopoietic stem cell transplantation. As of early 2024, the program is in early-stage clinical development, transitioning from preclinical studies to Phase 1.

Beyond the preview

Go deeper on PB2202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PB2202.

Explore the full profile